Has Christopher Croot, MD received payments from drug or device companies?

Yes. Drug and device makers reported $573,472 in general payments to Christopher Croot, MD across 806 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Croot, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Croot, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Croot, MD

Hematology & Oncology · Pikeville, KYNPI 1053318717

Payments from drug & device makers

$573,472in general payments, 2019–2025

Across 806 payments — averaging $711.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$286K
GSK$105K
Radius Health, Inc.$59K
Stemline Therapeutics Inc.$57K
Ipsen Bioscience Inc.$12K
Pfizer$9K
plus $46K from 54 others

$7,443in research payments, 2019–2025

Across 2 payments — averaging $3721.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$7K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	101	$286,043
GSK	38	$104,562
Radius Health, Inc.	5	$59,465
Stemline Therapeutics Inc.	10	$56,727
Ipsen Bioscience Inc.	3	$11,920
Pfizer	41	$8,955
Genentech, Inc.	2	$8,500
Jazz Pharmaceuticals Inc.	10	$8,372
Eli Lilly	3	$6,452
Hoffmann-la Roche Limited	1	$6,000
Novartis	82	$3,102
Daiichi Sankyo Inc.	76	$2,255
E.r. Squibb & Sons, L.L.C.	68	$2,186
AstraZeneca(2 entities)	38	$1,346
Johnson & Johnson(2 entities)	47	$1,272
Amgen	25	$798
Astellas Pharma US Inc	22	$637
Regeneron Healthcare Solutions, Inc.	17	$387
Bristol Myers Squibb	16	$350
Genentech USA, Inc.	16	$293
Incyte Corporation	13	$292
Pharmacyclics LLC, An Abbvie Company	10	$226
Beigene USA, Inc.	4	$219
Sanofi	11	$213
AbbVie	12	$210
Seagen Inc.	9	$204
Gilead(2 entities)	12	$204
Genmab U.S., Inc.	8	$188
Ipsen Biopharmaceuticals, Inc	4	$167
Array Biopharma Inc	10	$145
Lilly USA, LLC	8	$139
Foundation Medicine, Inc.	3	$119
Eisai Inc.	7	$119
Karyopharm Therapeutics Inc.	2	$117
Puma Biotechnology, Inc.	7	$103
AVEO Pharmaceuticals, Inc.	6	$93
Rigel Pharmaceuticals, Inc.	6	$91
Baxter Healthcare	1	$90
Takeda Pharmaceuticals U.S.A., Inc.	5	$89
Boehringer Ingelheim	4	$84
Exelixis Inc.	5	$77
Janssen Scientific Affairs, LLC	1	$67
Kyowa Kirin, Inc.	3	$58
Novocure Inc.	3	$43
Sun Pharmaceutical Industries Inc.	2	$41
Bayer	3	$36
Pharmacosmos Therapeutics Inc.	2	$33
ADC Therapeutics America, Inc.	2	$33
Taiho Oncology, Inc.	1	$30
EMD Serono, Inc.	2	$30
Adaptive Biotechnologies Corporation	1	$25
Teva Pharmaceuticals USA, Inc.	2	$24
Clovis Oncology, Inc.	2	$23
Aurobindo Pharma USA, Inc.	1	$22
Sobi, Inc	1	$22
Celltrion USA Inc.	1	$21
Tesaro, Inc.	1	$19
Legend Biotech USA Inc.	1	$18
Sumitomo Pharma America, Inc.	1	$17
Acrotech Biopharma Inc.	1	$16

How this compares

$573,472 in reported general payments places this provider in the 85th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$41,478

Medicare patients

175

Services billed

705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pikeville

Aasems JacobPikeville$236K
Mohamed El DinaliPikeville$18K
Joseph MalyLouisville$7M
Firas BadinLexington$6.7M
Laila AgrawalLouisville$6.3M
Jaspreet GrewalLouisville$4.2M
John VillanoLexington$3.2M
Rebecca RedmanLouisville$2.1M
Vivek SharmaLouisville$1.9M
Rohit KumarLouisville$1.6M

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →